{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 12,
  "pageCount": 415,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "Uses social media screenshots as primary evidence to build a case against the drug's safety profile.",
  "elementsJson": [
    "paragraph",
    "screenshot"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/12",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-12",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "You don’t have to be a statistician to extrapolate VYKAT XR’s potential to put many more children in the ICU over the coming months.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acab-b8fa8f25c950",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.86,
        "x": 0.07,
        "y": 0.7
      },
      "kind": "image",
      "text": "Three social media comment screenshots.",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31366a86-6703-4102-afbc-05c2bb99aaaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.59
      },
      "kind": "list",
      "text": "1st post: July 20, patient admitted July 18 with pulmonary edema. 2nd post: July 27, patient 25, hospitalized 4 days on oxygen. 3rd post: July 27, gradual onset of symptoms over 2 months.",
      "attrs": null,
      "subkind": "comparison",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b361638-0b7d-4eab-aff1-8aa582d9046a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.86,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "We’ll explain shortly. For now, the key point is that uncontrolled fluid retention leads to pulmonary edema, with a 20%-50% fatality rate by setting; after progression to congestive heart failure, the fatality rate is higher. You don’t have to be a statistician to extrapolate VYKAT XR’s potential to put many more children in the ICU over the coming months. The trend is clear. The hospitalizations that parents have begun to report in recent weeks are on a very small base. The timeline of events suggests that these patients were in the initial cohort in the first weeks of availability, when the denominator of new, drug-naïve patients may have been only a few dozen. We noticed the first parental report of potential heart failure on July 20 – the patient was admitted on July 18th. The parent indicates her child had been on drug for 2 months - therefore since mid-May - and that the symptoms creeped up gradually. Thus, the patient was filled VYKAT XR within about a month of commercial availability, when n=?.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81638e44-bfc6-4ba1-b388-7120bd39d808",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Not good at all!!! We have been in the hospital since Friday!!! Retained fluid all over especially his lungs with potential heart failure. Stopping Vykat aka diazoxide choline for good!!! — Facebook User",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64cd-733b-acab-be7b3803b12e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.07,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "Source: Facebook groups – “Vykat discussion group”...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95db92e1-7266-4b3e-b1e3-cccd9d536667",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Fluid retention is a mechanistic feature of VYKAT XR, not a bug.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f6f9c84-ee1c-4ae4-bf70-1a540b80c32f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "expose_contradiction",
      "slug": null,
      "matchId": "d3d80ae9-ab64-4cd2-80db-a79e2036a76b",
      "evidence": "Contrasts company claims (implied) with patient reports of adverse events.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}